Peptide secreted by
Among the fewer than 10 proteins primarily secreted by the species Lactobacillus plantarum , there is one of 30 kDa that contains an internal fragment without cleavage sites for the most important intestinal proteases and characterized by having a serine and threonine content of at least 50%. The genetic information encoded in this fragment, designated ST peptide, has been used for producing and purifying the peptide, thus making it possible to conduct various tests in vitro. To summarize, the ST peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the ST peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases.
1. An ST peptide with immunomodulating and/or anti-inflammatory properties comprising an amino acid sequence having at least 95% homology with SEQ ID NO:1.
2. The ST peptide of claim 1 wherein the ST peptide is derived from a protein secreted by a lactic acid bacterium.
3. The ST peptide of claim 2 wherein the lactic acid bacterium is a strain of Lactobacillus plantarum selected from the following group: Lb. plantarum NCIMB 8826, Lb. plantarum 299V, and Lb. plantarum BMCM12.
4. The ST peptide of claim 1 comprising the amino acid sequence of SEQ ID NO:1.
5. A functional foodstuff comprising a therapeutically effective amount of the ST peptide of claim 1 .
6. A pharmaceutical composition or medicinal product comprising a therapeutically effective amount of the ST peptide of claim 1 .
7. A cosmetic comprising the ST peptide of claim 1 .
8. The ST peptide of claim 1 wherein the amino acid sequence has a serine/threonine content of at least 50%.
9. The ST peptide of claim 1 wherein the peptide comprises at least a 30 kDa fragment that lacks a cleavage site for at least one intestinal protease.
10. The ST peptide of claim 9 wherein the intestinal protease comprises pepsin, trypsin, or chymotrypsin.
11. A method for treating an inflammatory intestinal disorder, the method comprising: administering to a subject a therapeutically effective amount of a composition comprising a polypeptide having at least 95% amino acid sequence homology with SEQ ID NO:1.
12. The method of claim 11 wherein the intestinal disorder comprises an inflammatory bowel disease or a celiac inflammation.
13. The method of claim 12 wherein the inflammatory bowel disease comprises Crohn's disease, ulcerative colitis, or pouchitis.
14. The method of claim 11 wherein the intestinal disorder is caused by an autoimmune disease or a disease caused by deregulation in the composition of the intestinal microbiota.
15. The method of claim 11 wherein a therapeutically effective amount of a composition is an amount effective to induce dendritic cells in the subject to produce an anti-inflammatory cytokine.
16. The method of claim 15 wherein the anti-inflammatory cytokine comprises IL-10.
17. The method of claim 11 wherein a therapeutically effective amount of a composition is an amount effective to inhibit dendritic cells in then subject from producing a pro-inflammatory cytokine.
18. The method of claim 17 wherein the pro-inflammatory cytokine comprises IL-12 or IL-6.